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Background: A clinical stability (CS) evaluation is thought to be important in community-
acquired pneumonia (CAP) treatment, but evidence concerning the time to CS (TCS) remains
lacking.
Methods: Among consecutive patients hospitalized with pneumococcal pneumonia, relation-
ships between TCS and other clinical outcomes were examined, and predictors and a predic-
tive TCS score were derived from patient characteristics on admission.
Results: A total of 144 patients were enrolled, including 46% and 27% with moderate and se-
vere pneumonia, respectively, defined by the pneumonia severity index (PSI). The median
TCS was 2 days, and was significantly correlated with the length of hospital stay
(r Z 0.595); a longer TCS was significantly associated with the more presence of poor clinical
outcomes and ICU stays (adjusted odds ratios: 1.359 and 1.366, respectively). A multivariate
Cox proportional hazard model revealed an absence of bilateral pneumonia (hazard rate
(HR): 2.107) or bacteremia (HR: 2.520), and mild or moderate pneumonia (HR: 2.798 and
2.515, respectively, versus severe) as predictors of CS. A predictive score had moderate
discriminating power for the prolonged TCS (area under the curve: 0.76), and provided similar
predictive values for poor clinical outcomes and ICU stays. A score of 3 or more points indi-
cated the prolonged TCS, with a sensitivity and specificity of 73.3% and 70.9%, respectively.68 76 4131; fax: þ81 568 74 4516.
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Time to clinical stability: predictors and impact 807Conclusions: Because TCS has a significant relationship with other clinical outcomes of pneu-
mococcal CAP, the prediction of TCS might lead to the prevention of complications or an
earlier transition to oral therapy. Future studies are warranted to validate these results.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Community-acquired pneumonia (CAP) is a significant cause
of morbidity and mortality worldwide; the most etiologic
pathogen is thought to be Streptococcus pneumoniae.
Therefore, it is crucial to reveal an accurate clinical picture
of pneumococcal pneumonia to determine an appropriate
treatment strategy for CAP. Recently, clinical stability (CS)
has received attention as a clinical indicator of CAP in
addition to mortality, length of hospital stay (LOS), and the
use of mechanical ventilation. CS is a useful indicator of the
appropriate timing to transition from intravenous to oral
antibiotics and for hospital discharge [1,2]. Moreover, the
time to CS (TCS) has been shown to affect clinical outcomes
after discharge [3e5]. Both CS and TCS seem to play an
important role in the treatment and clinical course of CAP.
Up until now, the principal purpose of a primary CAP evalu-
ation has been to predict the population with the highest
mortality. In addition, it is of importance in the reduction of
patient burden, medical cost, and the emerging risk of drug-
resistant pathogens to switch low-risk patients to an oral
therapy as early as possible. If TCS can be predicted on
admission as an indicator of therapeutic efficacy, new
treatment strategies for CAP might be formulated in com-
bination with the previously existing predictive method of
mortality: within the same severity category, more intensive
care to prevent complications or an admission to an ICU
rather than amedical ward could be indicated for patients at
a high risk of a prolonged TCS, or an earlier transition to an
oral therapy could be considered for those at a low risk for a
prolonged TCS. However, in CAP, only some studies have
reported factors affecting the TCS [6e8]; especially for
pneumococcal pneumonia, few have been investigated [9].
We conducted a pilot study in patients with pneumo-
coccal pneumonia and aimed to reveal the relationships
between TCS and other clinical outcomes of CAP, and to
derive the predictors and a predictive score of TCS using
patient characteristics and examinations available on
admission.
Methods
Patients and methods
The study population consisted of consecutive adults (aged
over 18 years) admitted to our hospital with a diagnosis of
pneumococcal pneumonia between January 2005 and June
2013. We excluded cases whose final diagnosis was not
pneumococcal pneumonia, those who died during hospital-
ization, those admitted for any reason within the previous
30 days, cases diagnosed with human immunodeficiency
virus infection, and those with a prescription for more than
20 mg of prednisolone or an equivalent daily. Patients with
malignant disease who had received immunosuppressivetreatment or who were apparent endstage were also
excluded.
The patient characteristics and clinical outcomes were
retrospectively collected from electronic medical records.
This study was approved by the institutional review board
of Komaki City Hospital (No. 131018). The requirement for
informed consent was waived because of the retrospective
nature of the study.
Definition and data collection
CAP was diagnosed when patients had both acute inflam-
matory symptoms, such as fever or severe cough, and new
infiltration on a chest radiograph suggestive of pneumonia.
For the diagnosis of pneumococcal pneumonia, at least one
factor was needed from a specimen obtained within 24 h of
admission: identification of S. pneumoniae from a culture
of sputum or blood at >1þ (equivalent to 105 CFU/mL),
identification of S. pneumoniae from pleural effusion, or a
positive result from a urinary antigen test (UAT) (Binax NOW
S. pneumoniae urinary antigen, Binax, Inc., Scarborough,
ME, USA). The sputum was available when its Geckler grade
was >3. The patients with only a positive UAT result were
included unless they had an apparent respiratory infection
within 3 months of admission or if any microbe other than S.
pneumoniae was identified in the specimen.
As for the patient characteristics, age, gender, the
presence of nursing home care associated pneumonia
(NHCAP), comorbidities, and smoking history were recor-
ded. Comorbidities were identified using the Charlson Co-
morbidity Score (CCI) [10] and the presence of chronic lung
disease or diabetes was noted. The use of statins or proton
pump inhibitors was also recorded.
For the severity evaluation on admission, a Simplified
Acute Physiology Score 3 (SAPS 3) [11], an A-DROP scoring
system (Table 1) [12] as recommended by the Japanese Res-
piratory Society, and a Pneumonia Severity Index (PSI) [13]
were scored. The A-DROP score was classified into 3 cate-
gories asmild,moderate, or severe and extremely severe; the
PSI was similarly categorized as mild (class I/II/III), moderate
(class IV), or severe (class V). The value for serum C-reactive
proteins (CRP) on admission was recorded as a biomarker.
An evaluation of chest radiographs on admission was
performed independently by two experienced pneumolo-
gists, and the presence of pleural effusion and bilateral
pneumonia were interpreted.
If Streptococcus pneumonia was isolated, its drug-
resistance was defined by the National Committee for
Clinical Laboratory Standards (NCLLS) [14], and a resistant
pathogen was defined as a minimum inhibitory concentra-
tion (MIC) >0.12 mg/mL for penicillin G.
It was recorded whether the initial therapy was a com-
bination therapy of antibiotics and whether the therapy
was inappropriate with respect to the drug sensitivity of the
pathogen, if available.
Table 1 The A-DROP scoring system for the severity of
community-acquired pneumonia. Each factor was assigned
one point, and the severity was determined by the total
score calculated by adding all the points.
Factor
Age Male S 70 y.o., female S 75 y.o.
Dehydration Blood urea nitrogen S 21 mg/dL
Respiratory failure PaO2 & 60 Torr or SpO2 & 90%
Orientation disturbance Confusion
Blood pressure Systolic blood pressure & 90 mmHg
Severity Total points
Mild 0
Moderate 1 or 2
Severe 3
Extremely severe 4 or 5
Table 2 Patient characteristics. Data are shown as a
number (%) or the median (interquartile range).
Patient characteristics
Age (y.o.) 71 (66e81)
Gender (M/F) 87/57
NHCAP (yes) 20 (13.8)
Smoking history (yes) 84 (60.0)
Glasgow Coma Scale 15 (15e15)
Comorbidities and medications
Chronic pulmonary disease 52 (36.1)
Diabetes 36 (25.0)
Charlson Comorbidity Index 2 (1e3)
Statin prescription 12 (8.3)
Proton pump inhibitor prescription 10 (6.9)
Examinations and therapies
Serum C-reactive protein (mg/dL) 14.5 (9.0e25.2)
Pleural effusion 18 (12.5)
Bilateral pneumonia 41 (28.4)
Bacteremia 14 (11.7)
Mixed pathogen 10 (9.9)
Resistant pneumococcus 19 (18.8)
Combination therapy 9 (6.3)
Inappropriate therapy 19 (18.8)
Severity scores
SAPS 3 59 (53e65)
A-DROP
Mild 27 (18.8)
Moderate 84 (58.3)
Severe þ extremely severe 33 (22.9)
PSI
Mild 30 (27.5)
Moderate 49 (45.0)
Severe 30 (27.5)
Outcomes
Time to clinical stability (d) 2 (1e4)
Length of hospital stay (d) 8 (6e13)
Clinical poor outcomes (yes) 14 (9.7)
ICU stay (yes) 26 (18.0)
NHCAP Z nursing- and healthcare-associated pneumonia,
PSI Z Pneumonia Severity Index, SAPS 3 Z Simplified Acute
Physiology Score 3.
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The American Thoracic Society (ATS) 2007 criteria were
applied for CS [15], including all the following variables,
detected during the same day after hospital admission:
body temperature <37.8 C, heart rate <100 beats/min,
systolic blood pressure >90 mmHg, oxygen saturation >90%
or PaO2 >60 mmHg in room air, respiratory rate <24/min,
normal mental status, and the capacity for appropriate oral
intake. In cases without consecutive measurements of
respiratory rate, the presence of dyspnea was substituted.
All variables were assessed every day, and TCS was defined
by the number of days until reaching CS.
A poor clinical outcome was defined as the need for
mechanical ventilation, including non-invasive ventilation,
and/or inotropic support. As for the other outcome mea-
sures, the presence of an ICU stay, including both direct
admission and transfer from the general wards, and the
length of hospital stay (LOS) were also collected.
Statistics
The data are presented as the median (interquartile range,
IQR). TCS was related to the presence of poor clinical
outcomes and ICU stay by a ManneWhitney U-test, and the
odds ratio (OR) was calculated and adjusted by severity on
admission using a logistic regression model to examine the
effect of poor clinical outcomes and ICU stay on the TCS. To
investigate the relationship between the LOS and the TCS,
Spearman’s rank correlation test was performed.
The predictors for TCS were determined by using a
multivariate Cox proportional hazard model including
baseline factors with p-values <0.1 from the univariate
analysis. To derive the predictive score for the prolonged
TCS, which was defined if the TCS was over the median
value, the beta-coefficient of each significant predictor was
calculated using a logistic regression model and predictive
scores were assigned according to their coefficients [16].
The area under the curve (AUC) of the receiver operating
characteristic curve was examined to assess the discrimi-
native ability of the predictive score for the prolonged TCS
and the occurrence of poor clinical outcomes or an ICU stay.A p-value <0.05 was considered statistically significant,
and the statistical analyses were performed mainly on SPSS
version 20 (IBM, Armonk, NY, USA).
Results
Within the study period, 1219 consecutive patients were
hospitalized because of pneumonia, of whom 164 were
diagnosed with pneumococcal pneumonia. After excluding
the deceased cases (mainly due to 11 dead patients), 146
patients met our criteria. In addition, two patients with
discrete values resulting from prolonged enteral nutrition
or mechanical ventilation (Fig. S1) were also excluded, and
finally, 144 patients were included in this study and were
available for an evaluation of TCS.
The patient characteristics were shown in Table 2. The
median age was 71 years (IQR: 66.0e81.7) and 39.5% of the
Figure 1 The relationship between the time to clinical sta-
bility and the length of hospital stay. Spearman’s rank corre-
lation test indicated a significant correlation (r Z 0.595,
p < 0.0001).
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included patients of the relatively advanced age and
comorbidities with the median CCI of 2. Using A-DROP and
PSI, mild and severe cases each accounted for approxi-
mately one-fifth of the cases.
The UAT had the highest performance and positive rate
within the microbial examinations (Table S1). A drug-
sensitivity test was obtained for 101 patients (70.1%), of
whom 19 (18.8%) were considered to have resistant path-
ogens, with 4 cases considered highly resistant.
The median TCS value was 2 days, and poor clinical
outcomes and ICU stays were detected in 14 (9.7%) and 26
patients (18.0%), respectively. The median LOS was 8 days
(IQR: 6e13).
The TCS of patients with poor clinical outcomes or ICU
stays were significantly longer than those of patientsTable 3 Variables affecting the time to clinical stability. Univa
proportional hazard model. The multivariate analysis was perform
analysis.
Univariate
p Value Hazard
rate
9
i
C-reactive protein (per 1 mg/dL) 0.0820 0.999 0
Bilateral pneumonia (no) 0.0003 2.074 1
Bacteremia (no) 0.0085 2.209 1
SAPS 3 (per point) 0.0638 0.971 0
A-DROP
Mild 0.0021 2.259 1
Moderate 0.1483 1.349 0
Severe þ extremely severe Reference
PSI
Mild <0.0001 3.243 1
Moderate 0.0028 2.084 1
Severe Reference
PSI Z Pneumonia Severity Index, SAPS 3 Z Simplified Acute Physiolowithout (5.5 days (IQR: 2.5e15.5) versus 2.0 days (IQR:
1.0e4.0), p < 0.001; 5.0 days (IQR: 3.0e5.0) versus 2.0 days
(IQR: 1.0e3.0), p < 0.001, respectively). The ORs of the
prolonged TCS (defined as equal or more than 3 days) in the
presence of a poor clinical outcome or an ICU stay were
1.359 (95% confidence interval (CI): 1.099e1.681,
p Z 0.0047) and 1.366 (95% CI: 1.107e1.687, p Z 0.0037),
respectively, after being adjusted by a logistic regression
model using PSI, A-DROP, and SAPS 3. Moreover, the TCS
was significantly correlated with the LOS (r Z 0.595,
p < 0.0001) (Fig. 1). The TCS was shown to have statistically
significant relations to other outcome measures related to
CAP, such as LOS, ICU stay and clinical poor outcomes,
independently of disease severity.
The result of univariate analyses for prolonged TCS of all
the variables were shown in Table S2. A multivariate anal-
ysis using six factors with p-values <0.1 from the univariate
analysis revealed bilateral pneumonia, bacteremia, and PSI
severity category as the significant predictors (Table 3).
Those with the absence of bilateral pneumonia or bacter-
emia took approximately twice as early to reach CS, and
cases in the moderate and mild PSI categories reached CS
approximately two and three times faster, respectively,
than severe cases. Specifically, the presence of bilateral
pneumonia and bacteremia doubled the TCS and the TCS
for mild or moderate pneumonia was one-third or one-half
shorter than that of severe pneumonia. Comorbidities,
resistant pathogens, and initial treatment did not affect
the TCS. Using these three factors, a TCS predictive score
was calculated using a logistic regression model (Table 4).
This score provided moderate predictive power for the
prolonged TCS, with an AUC of 0.76 (95% CI: 0.655e0.973)
(Fig. 2). A total score of 3 or more points indicated the
prolonged TCS with 73.3% and 70.9% sensitivity and speci-
ficity, respectively. This score was found to have similar
predictive power for poor clinical outcomes and the pres-
ence of an ICU stay (AUC 0.67: 95% CI: 0.516e0.826 and
0.72: 95% CI: 0.611e0.843, respectively).riate and multivariate analyses were performed using a Cox
ed using the variables with p-values <0.1 from the univariate
Multivariate
5% Confidence
nterval
p Value Hazard
rate
95% Confidence
interval
.977e1.000 0.7224 1.000 0.998e1.002
.394e3.087 0.0209 2.107 1.119e3.965
.224e3.987 0.0100 2.520 1.247e5.090
.942e1.002 0.7988 1.005 0.969e1.041
.343e3.801 0.0941 2.450 0.858e6.994
.899e2.025 0.4141 1.285 0.704e2.346
Reference
.845e5.701 0.0278 2.798 1.119e6.998
.288e3.372 0.0069 2.515 1.288e4.911
Reference
gy Score 3.
Table 4 Predictive scores for the prolonged time to clinical stability. Each point was assigned by weighting it by the coef-
ficient determined in the multivariate logistic regression analysis.
Beta-coefficient p Value Odds ratio 95% Confidence interval Point
PSI
Mild Reference 1.000 0
Moderate 1.632 0.0497 0.195 0.038e0.912 2
Severe 2.818 0.0012 0.060 0.011e0.327 3
Bacteremia 1.622 0.0271 0.198 0.047e0.832 2
Bilateral pneumonia 1.108 0.0396 0.330 0.115e0.949 1
PSI Z Pneumonia Severity Index.
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TCS was evaluated among 144 patients hospitalized for
pneumococcal pneumonia. A longer TCS was associated
with the more presence of poor clinical outcomes and ICU
stays, and significantly correlated with LOS, independent of
disease severity on admission. The presence of bacteremia,
bilateral pneumonia, and PSI severity category were the
significant predictors of prolonged the TCS. Predictors of
TCS remain unclear; especially for pneumococcal pneu-
monia, none have reported a predictive score.
In CAP treatment, reaching CS is important in clinical
decision making. Because clinical deterioration was re-
ported in only <1e2% of patients after reaching CS
[7,17,18], it is useful as a surrogate in determining treat-
ment duration [19,20] and when to switch to oral therapy
[1,2]. Once reaching CS, oral therapy is indicated, even for
bacteremic pneumococcal pneumonia [21]. Some have re-
ported the effects of CS/TCS on CAP outcomes after
discharge, reporting CS as an indicator of discharge [3e5].
This study also found a significant relationship betweenFigure 2 A receiver operating characteristic curve of the
predictive score for the prolonged time to clinical stability. The
area under the curve was 0.76 (95% confidence interval:
0.655e0.973).TCS, poor clinical outcomes, and ICU stays; both CS and TCS
seem to be important indicators in CAP treatment.
In general, TCS is reported as 2e4 days [3,6,7], but
knowledge regarding a prolonged TCS remains lacking.
Using Halm’s definition [7], Menendez et al. showed that
dyspnea, confusion, pleural effusion, multi-lobular pneu-
monia, PSI classes III/IV, and adherence to CAP guideline
were factors prolonging TCS in 1424 CAP patients [6]. Bor-
don et al. extracted pneumococcal pneumonia patients
from a large CAP cohort and reported that male sex, dia-
betes, and HIV infection were predictors of the short TCS,
and alert mental status, body temperature >104 F or
<96 F, respiratory rate >30/min, PaO2 <60 Torr, the
presence of a cavity on chest radiograph, neoplastic dis-
ease, liver disease, cerebrovascular accidents, and ICU
admissions were predictors of the prolonged TCS [9].
However, they did not evaluate a general severity index or
serum biomarkers, the population had a lower prevalence
of 4.4% for bacteremia, and they used ATS 2001 definitions
for CS criteria [22]; all these factors may have influenced
the differences from the present study.
Some studies detected multi-lobular pneumonia, pleural
effusion, PSI scores >90, chronic liver disease, leukocyto-
penia, thrombocytopenia, dyspnea academia, confusion,
Legionella pneumonia, and higher serum CRP values as
predictors of clinical failure [6,23e27]. Only one reported
in a population with pneumococcal pneumonia that chronic
liver disease, higher serum CRP values, and higher serum
creatinine were risk factors, and that COPD was a protec-
tive factor for complicated pneumonia [28].
Previous studies rarely investigated predictors or pre-
dictions of TCS, especially for pneumococcal pneumonia; to
our knowledge, this is the second such study.
Bacteremic CAP is associated with worse clinical out-
comes than non-bacteremic CAP. Especially for pneumo-
coccal pneumonia, higher rates of bacteremia of 10%e20%
were identified [29], similar to the results of the present
study, and longer TCS [21] and higher mortality [30] were
described in bacteremic cases. However, clinical outcomes
in pneumococcal pneumonia were also reported to be
equivalent, whether or not bacteremia was present, and
the effect of bacteremia on TCS/CS is controversial [9,31].
Bilateral pneumonia is a minor criterion for severe
pneumonia in the ATS guidelines [15], and is thought to
affect deterioration [6,23].
The relationship between PSI and TCS has already been
described as a disease-specific severity index [6e8,32].
Confusion, Respiratory rate, Blood pressure and age 65
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tive power to PSI in discriminating the CS within 7 days [8].
Because of the lack of apparent CS definitions, a wide
range of TCS values from 3 to 7 days were reported within
the same populations according to different definitions
[7]. However, among the recently available TCS criteria
[7,15,22], a similar predictive power for clinical deterio-
ration was reported [17,18]. Moreover, serum biomarkers
such as CRP and procalcitonin were shown to have addi-
tional value than the modified Halm’s criteria alone [33].
Regardless, a simple, standardized definition capable of
daily evaluation is needed.
Limitations
First, this study was retrospective in nature, and has a
relatively small sample size. Missing data were inevitable;
especially, SAPS 3 calculations were performed for only 57%
of patients. In general, CAP is thought to be a very het-
erogeneous disease caused by many varieties of etiologic
pathogens, of which half are unknown [12], and is affected
by many clinical factors such as comorbidities. Strengths of
this study include that it enhances the effects of patient
characteristics on the results, as it consisted of a mostly
homogeneous population, including only pneumococcal
pneumonia, and it examined more factors, including statin
prescriptions and resistant pathogens. Regardless, our re-
sults should be validated by a prospective study in a larger
population.
A second limitation concerns microbial examinations.
We only included cases with only positive UAT, which may
include false-positive results, with the reported specificity
of 95% [34]. In addition, this study did not evaluate pneu-
mococcal serotypes, as no commercial kit is available in
Japan. Many investigations have revealed the effect of
serotypes on the clinical course of pneumococcal diseases
[35]; in future studies, pneumococcal serotype should be
examined.
Third, we substituted dyspnea as a CS criterion in cases
without consecutive respiratory rate measurements. In
Japan, respiratory rate measurements are not performed
frequently; therefore, respiratory rate was excluded from
the A-DROP score recommended by the Japanese Respira-
tory Society (Table 1). To be more objective, an original
Japanese definition of CS, including a respiratory rate
substitute, might need to be derived and validated.
Conclusion
In this pilot study, TCS was confirmed as an important in-
dicator relevant to LOS, poor clinical outcomes, and ICU
stays. Bacteremia, bilateral pneumonia, and PSI severity
category were detected as predictors prolonging TCS by
two to three times. Predictive scores greater than or equal
to 3 points indicated the prolonged TCS with 73.3% and
70.9% sensitivity and specificity, respectively.
The prediction of the prolonged TCS, that is, pneumonia
with a high risk of complications, may lead to preventive
interventions in high-risk groups and an earlier transition to
oral therapy in low-risk populations. A future prospective
study is warranted to validate these predictors andpredictive scores among patients within a larger CAP
population.
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